Atul Deodhar, ACR 2021: Efficacy of Deucravacitinib by Baseline DMARD Use in Psoriatic Arthritis
It was a pleasure to discuss with Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) the results from the further exploratory analysis of the phase 2 trial (NCT03881059) investigating the TYK2 inhibitor, deucravacitinib, in patients with psoriatic arthritis treated with and without background conventional synthetic DMARDs.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study’ (ABSTRACT NUMBER: 1352) was presented at the ACR Convergence, 5-9 November 2021.
- Could you tell us a little about deucravacitinib, its mechanism of action and its potential advantages over other kinase inhibitors? (0:14)
- What did the phase 2 study teach us about deucravacitinib in patients with active PsA? (1:36)
- Could you tell us about the current exploratory analysis of the phase 2 study data, and its findings? (3:25)
Disclosures: Prof. Atul Deodhar has been a consultant/ advisory board member for AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Glaxo Smith & Kline, Janssen, Moonlake, Novartis, Pfizer and UCB, and received research grants from AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Psoriatic Arthritis
Xenofon Baraliakos, ACR 2022: Comparison of BASDAI vs. ASDAS in evaluating symptoms of axial involvement in psoriatic arthritis
In this post-hoc analysis of the DISCOVER-1 and DISCOVER-2 studies, which investigated guselkumab in axial psoriatic arthritis, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS) were compared in evaluating symptoms of axial involvement in psoriatic arthritis. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, […]
Laure Gossec, ACR 2022: Guselkumab efficacy in psoriatic arthritis assessed by multi-domain composite indices
The Phase 3b COSMOS study (NCT03796858) investigated efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to TNF inhibitors. touchIMMUNOLOGY caught up with Prof. Laure Gossec (Sorbonne Université, Paris, France) to discuss her analysis assessing efficacy of guselkumab by multi-domain composite indices. This information is brought to you by Touch […]
Laure Gossec, EULAR 2022: Guselkumab for Psoriatic Arthritis – An Analysis of the Phase 3b COSMOS Trial
The Phase 3b COSMOS trial (ClinicalTrials.gov Identifier: NCT03796858) investigated guselkumab in patients with psoriatic arthritis that had an inadequate response to anti-tumor necrosis factor alpha (Anti-TNF Alpha) therapy. We were delighted to speak to Professor Laure Gossec (Pitie-Salpetriere Hospital and Sorbonne Universite, Paris, France) to discuss the findings from her analysis of the phase 3b […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!